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BACKGROUND & AIMS: Developing antigen-speciﬁc approa-
ches for diagnosis and treatment of celiac disease requires a
detailed understanding of the speciﬁcity of T cells for
gluten. The existing paradigm is that T-cell lines and clones
from children differ from those of adults in the hierarchy
and diversity of peptide recognition. We aimed to charac-
terize the T-cell response to gluten in children vs adults
with celiac disease. METHODS: Forty-one children with
biopsy-proven celiac disease (median age, 9 years old; 17
male), who had been on strict gluten-free diets for at least 3
months, were given a 3-day challenge with wheat; blood sam-
ples were collected and gluten-speciﬁc T cells were measured.
We analyzed responses of T cells from these children and from
4 adults with celiac disease to a peptide library and measured
T-cell receptor bias. We isolated T-cell clones that recognized
dominant peptides and assessed whether gluten peptide
recognition was similar between T-cell clones from children
and adults. RESULTS: We detected gluten-speciﬁc responses
by T cells from 30 of the children with celiac disease
(73%). T cells from the children recognized the same pep-
tides that were immunogenic to adults with celiac disease;
deamidation of peptides increased these responses. Age and
time since diagnosis did not affect the magnitude of T-cell
responses to dominant peptides. T-cell clones speciﬁc for
dominant a- or u-gliadin peptides from children with celiac
disease had comparable levels of reactivity to wheat, rye,
and barley peptides as T-cell clones from adults with celiac
disease. The a-gliadin–speciﬁc T cells from children had
biases in T-cell receptor usage similar to those in adults.
CONCLUSIONS: T cells from children with celiac disease
recognize similar gluten peptides as T cells from adults with
celiac disease. The ﬁndings indicate that peptide-based
diagnostics and therapeutics for adults may also be used for
children.TCL, T-cell lines; TCR, T-cell receptor.
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Immunity; Pediatric; T-Cell Epitope.etailed understanding of the function and speciﬁcityDof T cells responsible for autoimmunity is widely
expected to translate to more effective strategies to di-
agnose, treat and prevent autoimmune disease.1 Among all
the autoimmune diseases, celiac disease (CD) is the only one
for which there is broad consensus on the identity of
immunodominant epitopes consistently recognized by
pathogenic CD4þ T cells.2 However, little is known about the
CD4þ T-cell response in children close to the time when the
immunological events responsible for CD are initiated.3
Understanding these early events is important, given the
rising incidence of CD4,5 and recent failures of large inter-
vention studies aimed at reducing the development of CD in
high-risk infants.6,7
Celiac disease is characterized by the presence of gluten-
dependent intestinal damage, autoantibodies to tissue
transglutaminase (tTG), and the presence of human leuko-
cyte antigen (HLA) genes that encode HLA-DQ2.5, HLA-
DQ2.2, and/or HLA-DQ8, responsible for presenting gluten
peptides to pathogenic CD4þ T cells.8 CD4þ T cells isolated
from intestinal tissue or circulating in blood after oral wheat
challenge in adult CD patients preferentially recognize
gluten peptides post-translationally modiﬁed (deamidated)
by tTG that include highly conserved epitopes.9,10 Approxi-
mately half or more of these wheat gluten-reactive CD4þ T
cells in HLA-DQ2.5þ CD patients recognize 1 of 2 over-
lapping epitopes derived from partially deamidated wheat
a-glaidin (PFPQPELPY: DQ2.5-glia-a1a or PQPELPYPQ:
DQ2.5-glia-a2).11,12 Several other epitopes, including 2 from
partially deamidated u-gliadin (PFPQPEQPF: DQ2.5-glia-u1
and PQPEQPFPW: DQ2.5-glia-u2), are also commonly
recognized by a substantial proportion of wheat gluten-
reactive T cells from the intestinal mucosa and in blood
after oral wheat challenge in adults with CD.13,14
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prospective observational studies indicate the onset of CD is
typically between 1 and 6 years of age.3 The only detailed
study to address the speciﬁcity of the T-cell response to
gluten in children concluded that there were fundamental
differences to adults.15 Intestinal T-cell lines and clones
from children revealed far greater diversity of the gluten-
speciﬁc T-cell response, and included native gluten pep-
tides not dependent on deamidation. This has established
the prevailing dogma that the T-cell response to gluten in
children with CD nearer disease onset is fundamentally
different than that in adults with CD in terms of the hier-
archy and diversity of peptide recognition. This dogma has
remained unchallenged until the present study.
Our aim was to determine the hierarchy of gluten pep-
tides responsible for activating T cells freshly isolated from
blood after wheat challenge in children with CD and
determine whether T-cell recognition of gluten differed
between children and adults. Here we established the
speciﬁcity and hierarchy of the polyclonal T-cell response to
gluten in HLA-DQ2.5þ children with CD in vivo and deter-
mined the redundancy of peptide recognition and T-cell
receptor (TCR) gene usage to compare the speciﬁcity,
magnitude, maturity, and clonality of T-cell responses to
gluten between children and adults.Materials and Methods
Participants and Oral Wheat Challenge
The study was approved by the Human Research Ethics
Committees of The Royal Children’s Hospital (RCH, no. 32018),
the Walter and Eliza Hall Institute (no. 03/04) and the Royal
Melbourne Hospital (no. 2003.009) and by the Carlo Romano
Ethical Committee of the University of Naples, Federico II (no.
04/04/2012). All volunteers or their parents provided written
informed consent. Volunteers had biopsy-proven CD diagnosed
according to ESPGHAN criteria16 and were HLA-DQ2.5þ and
HLA-DQ8-. Volunteers followed a strict gluten-free diet for at
least the previous 3 months and were recruited by advertise-
ment in the Coeliac Victoria and Tasmania newsletter or during
attendance at RCH or the Section of Pediatrics, DISMET, Italy.
The Australian cohort consisted of 41 CD volunteers (3–17
years of age; median, 9 years; 17 M, 24 F) split into 3 age
groups: 3–5 years old, 6–10 years old, and 11–18 years old. An
additional 4 CD adults (18þ) were recruited for T cell com-
parisons (Supplementary Table S2). The Italian cohort con-
sisted of 10 HLA-DQ2.5þ CD volunteers (10–17 years of age;
median, 13 years old; 4 M, 6 F). Short-term (3-day) wheat
challenge and blood collection on day 6 (D6) after challenge
was performed as previously described,13 with daily bread
intake reduced for children (see Supplementary Materials and
Methods).Antigens
To optimize assessment with a limited blood volume, a
modiﬁed library containing wild-type and in silico-deamidated
versions of the most immunogenic wheat gliadin and glutenin
peptides described previously13 was assessed (n ¼ 70, 37 wild-
type, and 33 deamidated) (Supplementary Table S3). Whenblood volume allowed, an additional series of deamidated
peptides immunogenic in a large group of CD adults were also
assessed in the Australian cohort: barley hordein (n ¼ 22), rye
secalin (n ¼ 30), and oat avenin (n ¼ 2; 1 wild-type).13,17 Also
assessed were 7 sequences implicated in pediatric CD on the
basis of intestinal T-cell line (TCL) reactivity15 as wild-type and
deamidated versions at a 50% mixture of leucine and isoleucine
(Supplementary Table S3, indicated by “X”), and wild-type and
deamidated versions of peptides recognized by intestinal TCL
derived from adults with villous atrophy or potential CD in an
Italian cohort, containing g-gliadin epitopes and length vari-
ants18,19 (Supplementary Table S3) (additional information on
screening libraries and protein antigens is available in
Supplementary Materials and Methods).
Immunological Assays
IFN-g ELISpot, IFN-g secretion assay, T-cell cloning, and
TCR sequencing methods are described in Supplementary
Materials and Methods.
Statistical Analysis
Simpson’s diversity index was used to measure clonotype
diversity within individuals (details are shown in
Supplementary Materials and Methods). Two-tailed Mann-
Whitney U test or Kruskal-Wallis test was performed for
comparisons between 2 or more groups of paired data,
respectively. Contingency analysis was performed using either
the Fisher’s exact test or chi-square test. Statistical tests were
performed using Prism version 6 software (GraphPad, LaJolla,
CA). P values  .05 were considered signiﬁcant.
Results
Clinical Response to Oral Wheat Challenge
Forty-one Australian children (17 M: 24 F) with
conﬁrmed CD participated (Supplementary Table S1). Most
subjects presented with symptoms at diagnosis, with only 7
detected following screening based on positive family his-
tory. At the time of this study, children were between 3 and
17 years of age (median, 9 years) (Supplementary Table S2).
Each participant undertook a 3-day wheat challenge con-
sisting of 1 to 3 slices of wheat bread daily depending on
age. Most volunteers (31 of 41) had normal baseline CD
serology immediately prior to undertaking the challenge
(Supplementary Table S2). The wheat challenge induced
symptoms in 29 of 41 (71%) volunteers, which were mainly
gastrointestinal (such as nausea, bloating, abdominal pain
and vomiting) and comparable to that experienced by CD
adults after short-term wheat challenge.20 Four volunteers
(3–5 years of age, n ¼ 1; 6–10 years of age, n ¼ 2; 11–18
years of age, n ¼ 1) did not consume the entire serving of
gluten over 3 days due to vomiting (n ¼ 3) or poor toler-
ability (n ¼ 1), but analysis on day 6 (D6) was still per-
formed. Symptoms were fully resolved in 26 of 29 (90%) of
children by D6 with conservative management. The pro-
portion of symptomatic individuals did not vary by age
grouping (P ¼ not signiﬁcant [NS], chi-square test) or by
HLA-DQ2.5 zygosity (P ¼ NS, Fisher’s exact test). The
presence of symptoms did not correlate with a signiﬁcant
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peptide (P ¼ NS, chi-square test), although all volunteers
who experienced vomiting mounted a positive response to
gluten peptide(s). There were no differences in age or
degree of villous atrophy (Marsh 3A, 3B, or 3C) at time of CD
diagnosis between HLA-DQ2.5 homozygous and heterozy-
gous volunteers (P ¼ NS, chi-square test).Gluten-Speciﬁc T Cells Have Similar Speciﬁcity in
Children and Adults with CD
After oral wheat challenge, signiﬁcant IFN-g ELISpot
responses were detectable in most CD volunteers (30 of 41
[73%]) to at least 1 wheat gluten peptide (Figure 1 [peptide
details are shown in Supplementary Table S3]). Responses
to whole protein (gliadin and/or gluten) were less consis-
tent, present in 23 of the 30 wheat gluten peptide re-
sponders and in an additional 2 participants who did not
respond to any wheat gluten peptides. Each age group
contained a similar proportion of gluten peptide/protein
responders, 3–5 years of age; 10 of 13, 76.9%; 6–10 years ofFigure 1.Wheat-derived T-cell epitope hierarchy in pediatric ce
IFN-g ELISpot assays performed on peripheral blood mononuc
patients. Color coding represents responses above cutoff as
41–70%; yellow, 21–40%; green, 11–20%; and blue, 6–10%). A
gray, and protein responses greater then peptide responses in ye
are shown. H, HLA-DQ2.5 homozygous individuals. Deﬁned orage; 10 of 12, 83.3%; 11–18 years of age; 12 of 16, 75%
(P ¼ NS, chi-squared test). Signiﬁcant responses to deami-
dated gliadin, an a-gliadin peptide (LQPFPQPELPYPQPQ)
containing the T-cell epitopes DQ2.5-glia-a1a and a2
(hereafter named W02), and an u-gliadin peptide
(QPFPQPEQPFPWQ) containing the T-cell epitopes DQ2.5-
glia-u1 and u2 (hereafter named W03) were seen on day
6 (D6) following wheat challenge but not prior to D0
(Figure 2A [n ¼ 28]). A low positive response to deamidated
gliadin was detected in 1 volunteer on D0. Responses to the
positive control tetanus toxoid did not differ between D0
and D6 (Figure 2A). The presence of a T-cell response to
gluten or gluten peptide was not affected by positive CD
serology at baseline or DQ2.5 zygosity status (P ¼ NS for
both, Fisher’s exact test).
There was a clear preference for deamidated antigens
compared to their native counterparts (Figure 1 and
Figure 2B). The highest IFN-g ELISpot responses were
commonly noted to a gluten peptide compared to whole-
protein antigen (gliadin or gluten) in most cases (22 of 32
[69%], including 2 protein-only responders), suggestingliac disease. Numbers are raw spot-forming units (SFU) from
lear cells (PBMC) from wheat-challenged celiac disease (CD)
a percentage of maximal peptide SFU (red, >70%; orange,
ssay cutoffs are shown in purple, negative protein results in
llow. Only peptides that reached >70% in at least 1 individual
predicted peptide sequence cores are in bold; ND, not done.
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Figure 2.Wheat challenge induces gluten-speciﬁc T-cell responses in children with CD. Pediatric CD volunteers undertook
3-day oral wheat challenge, and T-cell responses to wheat-derived proteins and peptides were assessed by IFN-g ELISpot.
(A) Responses to deamidated gliadin, peptide W02 containing DQ2.5-glia-a1a/a2, and peptide W03 containing DQ2.5-glia-
u1/u2 prior to (D0) and after (D6) wheat challenge (background subtracted) are shown. Gluten-speciﬁc responses were
observed on D6 only and were signiﬁcantly higher than D0 responses (P < .05, Kruskal-Wallis), whereas no differences were
seen for tetanus toxoid. (B) Peptides W02 and W03 were tested in native and deamidated forms. Deamidation enhanced the
response to peptide in all ages (n ¼ 4, 3–5 years of age; n ¼ 7, 6–10 years of age; n ¼ 8, 11–18 years of age), some statistically
signiﬁcant (P < .05, Kruskal-Wallis). (C) Polyclonal responses to peptides described by Vader et al15 as immunogenic to TCLs
isolated from children. Line depicts response cutoff. (D) IFN-g ELISpot responses of n ¼ 9 Italian pediatric CD volunteers to
deamidated gliadin, W02, and W03 (background subtracted).
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the immune response to whole protein. Overall, participants
responded to a number of wheat gluten-derived peptides
(Figure 1). Raw results were normalized by expressing them
as a percentage of the maximal peptide response for that
individual, and a response >70% was taken to be domi-
nant.13 Responses >70% of the maximal peptide response
were seen in the majority of individuals against peptides
containing the immunodominant DQ2.5-glia-a1/2 and u1/2
epitopes or peptides with native or homologous versions of
these epitopes. Dominant responses to additional unrelated
wheat-derived peptide sequences were also detected in a
small number of individuals, including the gliadin-derived
sequence YEVIRSLVLRTLPN and the glutenin-derived se-
quences GQSGYYPTSPQQS and GLERPWQEQPLPPQ
(Figure 1). Non-response to gluten, gliadin and any gluten
peptide was signiﬁcantly associated with a poor response to
tetanus toxoid (P < .05, Mann-Whitney U test)
(Supplementary Figure 1). Following wheat challenge,
in vivo polyclonal T-cell responses against the novel
immunogenic gluten peptides described by Vader et al15were poor and detected in only 2 of 30 volunteers (6.7%)
to the sequence QPPFSEEQEQPLPQ (Figure 2C).
Immunogenic peptides were ranked by magnitude of
response to establish the hierarchy of gluten peptides
(Figure 1). Furthermore, “dominance scores” within each
age grouping and overall were calculated (Table 1). Twelve
of seventy wheat gluten peptides were associated with
dominance scores greater than or equal to 30 (an arbitrary
level) for all age groups. Notably, the most dominant 4
peptides across all age groups corresponded closely to those
observed in adults following wheat challenge13 and
included W02 (LQPFPQPELPYPQPQ) and W01 (LPYPQ
PELPYPQP), both of which contain the DQ2.5-glia-a1a or 1b
and a2 epitopes and were the 2 most immunogenic peptides
in adults,13 W06 (LQPFPQPELPFPQP) containing a homolog
of DQ2.5-glia-a1a, and W03 (QPFPQPEQPFPWQP) contain-
ing the DQ2.5-glia-u1/u2 epitopes. The dominance hierar-
chy also contained the native versions of W01, W02, and
W04 (QPFPQPQQPIPVQ) but their deamidated equivalents
were ranked higher in all cases (Table 1). An additional
3 peptides had dominance scores greater than 30 in the
Table 1.Dominance Scores for Wheat-Derived Peptides Measured in Children With Celiac Disease After Wheat Challenge
Peptide
name
Peptide sequence
(core in bold)
Gliadin
source
Deﬁned/predicted T-cell
epitopes
Dominance scores
3–5 y 6–10 y 11–18 y Mean for all ages
W02 LQPFPQPELPYPQPQ a DQ2.5-glia-a1a/a2 77 57 60 64
W01 LPYPQPELPYPQP a DQ2.5-glia-a1b/a2 65 72 51 62
W06 LQPFPQPELPFPQP a PFPQPELPF; PQPELPFPQ 58 53 54 54
W03 QPFPQPEQPFPWQP u DQ2.5-glia-u1/u2 65 51 46 54
W26 PFPLQPEQPFPQP u LQPEQPFPQ 46 62 35 47
W08 LQPFPQPELPYSQP a DQ2.5-glia-a1a 45 52 40 45
W04 QPFPQPEQPIPVQ u PFPQPEQPI; PQPEQPIPV 43 44 48 45
W01 (WT) LPYPQPQLPYPQP a DQ2.5-glia-a1b/a2 31 49 35 39
W02 (WT) LQPFPQPQLPYPQP a DQ2.5-glia-a1a/a2 30 43 35 37
W04 (WT) QPFPQPQQPIPVQ u PFPQPQQPI; PQPQQPIPV 33 43 31 36
W16 FPQPEQEFPQPQQ g PQPEQEFPQ 23 47 26 33
W13 LQPFPQPELPYLQP a DQ2.5-glia-a1a 34 32 30 32
W32 PFPEQPEQPFPQP g DQ2.5-glia-g4c 26 34 28 30
W05 QPFPQPEQPFSQQ g DQ2.5-glia-u1; PQPEQPFSQ 23 33 27 28
W07 QPFPQPEQPFCQQ g DQ2.5-glia-u1; DQ2.5-glia-g4d 40 20 16 24
NOTE. Dominance scores were calculated for each peptide as the mean score for each age group and the mean of all subjects
(percentage of maximal peptide response from Figure 1). Scores >30 are shaded in gray. Top 15 peptides dominant in one
subgroup are shown.
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contained sequences homologous to W03.
To further test the relevance of the immunogenic wheat
gluten peptides, wheat challenges were undertaken in a group
of Italian children (n ¼ 10, 10–17 years of age) with CD. As
lower blood volumes were collected, T-cell responses were
measuredagainst a limited selectionof the samewheat derived
peptides as above. Nine of ten volunteers responded to at least
1 peptide (Supplementary Table 4) with only a single CD child
not responding to any peptides or proteins (data not shown).
Six children had a positive response to wild-type or deami-
dated gluten proteins, and 4 to wild-type gliadin, 2 of which
also responded to deamidated gliadin (Supplementary
Table 4). Four of nine volunteers (44%) and 3 of 9 (33%)
responded to W02 and W03, respectively (Figure 2D). Strong
positive responses >40% of the maximal peptide response
were mainly against peptides containing DQ2.5-glia-a1/2 and
-u1/2 homologs (Supplementary Table 4). Some volunteers
also responded to unrelated gliadin and glutenin-derived
peptides (Supplementary Table 4). Consistent with the
Australian cohort of the same age range, bioactivity was
enhanced with deamidation, although some native peptides,
such as GQPGYYPTSPQQIGQ and IQVDPSGQVQWPQQ, induced
responses in some individuals. Background responses were
generally high (>10 spot forming units/well) (Supplementary
Table 4) and 2 individuals responded to either gluten protein
or peptide at D0 before oral wheat challenge (Figure 2D).
Age and Time From Diagnosis Do Not Affect the
Gluten-Speciﬁc T-Cell Response
Dose-response curves and half maximal effective concen-
tration (EC50) values were calculated in 17 children (n ¼ 4,3–5 years of age; n ¼ 8, 6–10 years of age; and n ¼ 5, 11–18
years of age) and 4 adults (18–70 years of age) based on T-cell
responses to W02 and W03 (Figure 3). Median EC50 were
similar across each agegroup forW03(Figure3A). EC50values
for W02 were similar between children aged 6–10 years,
11–18 years, and adults, but differences were observed
between 3–5 and 6–10 years of age (Figure 3A). EC50 values
were not statistically different between children who were
heterozygous and thosewhowere homozygous forHLA-DQ2.5
(Figure 3B), but a trend toward a lower EC50 in homozygotes
was observed. The overall magnitude of T-cell responses to
W02 and W03 was signiﬁcantly greater for volunteers who
were HLA-DQ2.5 homozygotes than for heterozygotes
(Figure 3C). This difference was not seenwhen comparing age
groups (P ¼ NS, Kruskal-Wallis test) (Figure 3D).
We also compared EC50 values based on the years since
diagnosis of CD to assess its impact on T-cell responses. As
expected, the elapsed time from diagnosis was lowest in the
youngest age group (3–5 years of age; 0.4–4.4 years of age;
median, 1 year, 6–10 years of age; 0.6–7.7 years of age;median,
3.3 years; and 11–18 years of age; 1–9.9 years of age; median,
3.6 years; P < .05, Kruskal-Wallis). Given the variability in
disease presentation and clinical diagnosis, true disease
durationwas not possible to determine. Ifweused an arbitrary
cut-off of wheat challenge occurring less or more than 2 years
from diagnosis, then median EC50 values calculated for both
W02 and W03 were not statistically different (Figure 3E).
Gluten-Speciﬁc T Cells Cross-React With
Hordein and Secalin Peptides
We sought to determine the level of barley and rye grain
cross-reactivity in wheat-speciﬁc T cells from CD children
Figure 3. Effects of age,
HLA-DQ2.5 zygosity, and
time since diagnosis on
gluten peptide T-cell re-
sponses. Peptides W02
and W03 were assessed in
a dose-ranging study in
pediatric and adult CD
volunteers following oral
wheat challenge. EC50
values were calculated and
compared: (A) between
age groups, (B) between
HLA-DQ2.5 homozygous
(n ¼ 8) and heterozygous
individuals (n¼ 10–13), and
(E) between volunteerswith
diagnoses less than2 years
prior to gluten challenge
(n¼ 8) or more than 2 years
(n ¼ 6–8). (C) ELISpot
response magnitude is
shown in homozygous
(n ¼ 7) and heterozygous
(n ¼ 22) individuals.
(D) ELISpot response mag-
nitude was categorized by
age (n¼ 7, 3–5 years of age;
n ¼ 10, 6–10 years of age;
and n ¼ 10, 11–18 years of
age). Median and inter-
quartile ranges are shown
(*P < .05, Kruskal-Wallis or
Mann-Whitney U test).
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induced by oral wheat challenge cross-reacted to a series of
peptides derived from barley hordein and rye secalin (n¼ 22)
(Figure 4). Fifteen of 22 CD children (68%) responded
to W03 containing DQ2.5-glia-u1/u2 (Figure 4) and, in
most cases, also responded to other peptides containing
homologous sequences within hordein and secalin, consis-
tent with the presence of a homologous T-cell epitope in
barley (DQ2.5-hor-1: PFPQPEQPF).
A T-cell clone (TCC) speciﬁc to DQ2.5-glia-a2 and 1
speciﬁc to DQ2.5-glia-u1/u2 were raised from 2 different
children with CD, and their recognition of comprehensive
wheat gliadin, barley hordein, and rye secalin peptide li-
braries were assessed (Figure 5). Peptide responses werecompared to those obtained from previously isolated TCC
from adults with CD who were tested against the same li-
braries.13 TCC 3007.28 (speciﬁc to DQ2.5-glia-a2) showed
minimal reactivity to hordein and secalin peptides, consis-
tent with the observation that peptides containing the
immunodominant wheat T-cell epitopes DQ2.5-glia-a1a and
DQ2.5-glia-a2 are infrequent in barley or rye (Figure 5,
positive response to 575 of 3329 peptides is shown by co-
lor; peptide sequences and nonreactive peptides are not
shown). In contrast, TCC speciﬁc to DQ2.5-glia-u1/2
showed substantially more immunoreactivity to a range of
hordein and secalin peptides that encompassed both epi-
topes. Notably, secalin and hordein cross-reactivity patterns
of the TCC from children were very similar to those raised
Figure 4. Cross-reactive
T-cell responses in children
with celiac disease after
wheat challenge. Numbers
are raw spot-forming units
(SFU) from IFN-g ELISpot
assays performed on pe-
ripheral blood mono-
nuclear cells (PBMC) from
wheat-challenged CD pa-
tients. Color coding repre-
sents signiﬁcant responses
as percentages of maximal
peptide SFU (red, >70%;
orange, 41–70%; yellow,
21–40%; green, 11–20%;
and blue, 6–10%). Deﬁned
or predicted peptide
sequence cores are in
bold.
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reactivity for TCC speciﬁc for DQ2.5-glia-u1/2 and more
restricted cross-reactivity for TCC speciﬁc for DQ2.5-glia-
a1a/a2 (Figure 5).
Gluten-Speciﬁc TCR Repertoires Are Similar in
Children and Adults with CD
We used T-cell receptor (TCR) diversity as a measure of
the maturation of the effector T-cell response and compared
between age groups. We sequenced the CDR3 region in
gluten-speciﬁc CD4þ T cells that were single-cell sorted
based on their secretion of IFN-g in response to gluten
peptide stimulation (Figure 6). Polyclonal T cells respond-
ing to W02 were assessed in an 11-year-old (C27), a 6-year-
old (C14), and an adult (A1) subject with CD. There was
clear bias in both Vb and Va subunit usage for all 3 vol-
unteers with an emphasis on TRBV 7-2 or TRBV 7-8 and
TRAV 26-1 for C27, TRBV 7-2 and TRAV 26-1 for C14, and
TRBV 7-2 and TRBV 29-1 and TRAV 26-1 for A1 (Figure 6A).
Simpson’s diversity index values for the CDR3 Va and CDR3
Vb chain sequences, which takes into account both the
number and distribution of sequences within samples, were
all close to 1 (Figure 6B), indicating similar clonal diversity
between samples. Most CDR3 sequences collected for TRBV
7-2 contained a conserved arginine (Arg) residue
(Supplementary Table 5), consistent with previous re-
ports.21 Clonal expansion within the TRBV 7-2 population
was evident due to repetitive sequences within the poly-
clonal population for each individual. Moreover, 1 public
clonotype was evident between volunteers A1 and C14, and
1 between C14 and C27. Sharing of TRBV7-2
CDR3 sequences was also evident between our
volunteers and the CD cohorts examined by Qiao et al21 and
Han et al,22 both of whom used tetramer-based sorting.
TCR sequences were obtained for 2 TCC, 1 isolated from
C27 (DQ2.5-glia-a2-speciﬁc) and 1 from a 17-year-old CD
volunteer C40 (DQ2.5-glia-a1a-speciﬁc). The DQ2.5-glia-a2-
speciﬁc TCC 3007.28 expressed TRBV 7-2 and theconserved Arg residue in the CDR3b region (sequence
SIRTTDTQ). The DQ2.5-glia-a1a-speciﬁc TCC 3072 1.14
expressed TRBV 29-1 (CDR3b sequence GTVWFTDTQ). Both
TCC expressed TRAV 26-1. There were no conserved
sequence motifs within the TRAV CDR3 region within the
polyclonal or clonal gluten-speciﬁc T-cell populations, but 2
CDR3a sequences were shared between C27 and C14 (data
not shown).
Discussion
Our assessment of gluten-speciﬁc T cells in HLA-DQ2.5þ
children with CD indicates remarkable consistency in T-cell
recognition of immunodominant wheat gluten epitopes,
speciﬁcally DQ2.5-glia-a1/a2 and DQ2.5-glia-u1/u2, and
conﬁrms the importance of deamidation in enhancing
bioactivity of most immunogenic peptides. The ﬁndings are
comparable to those in adults with CD from England, Italy,
Norway, and Australia.10,13,14,23 Although our focus on
immunogenic peptides in adults means this is not an unbi-
ased study of gluten T-cell epitopes in pediatric CD, our
ﬁnding that T-cell responses to select gliadin peptides were
generally greater than to whole gluten antigen suggests that
the contribution of other untested peptides to the total
gluten immune response is minimal. As the T-cell epitope
dominance hierarchy or strength of response based on
EC50s was not affected by age or time from diagnosis, our
results suggest that the recall T-cell response to speciﬁc
gluten peptides develops early in disease pathogenesis, is
well established when CD is eventually diagnosed, and re-
mains consistent over time.
Many features of the immunopathology of CD are com-
mon to adults and children. For instance, chronic ingestion
of gluten is associated with elevated levels of serum
immunoglobulin A (IgA) speciﬁc for tTG and both IgG and
IgA speciﬁc for highly conserved deamidated 5-mer peptide
motifs derived from gliadin.24,25 In contrast, in vitro data
from CD children suggested a lower rate of response to
dominant T-cell epitopes, a lower rate of dependence on
Figure 5. T-cell clone pro-
miscuity. T-cell clones
speciﬁc to DQ2.5-glia-a1a/
a2 or DQ2.5-glia-u1/u2
were tested against wheat,
barley, and rye peptide li-
braries by IFN-g ELISpots.
Positive responses are
shaded as follows: wheat,
blue; barley, orange; and
rye, green. Peptide se-
quences are not shown.
Nonreactive peptides were
removed.
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immunogenic peptides.15 Studies assessing peripheral blood
mononuclear cells (PBMC) from untreated children with CD
using in vitro culture (and no oral gluten challenge) detec-
ted responses to DQ2.5-glia-a1a and a2 in 30% or less of
children26 and proliferation was not detected.27 Vader
et al15 showed that only 8 of 16 TCL from 25 Dutch
children (1–12 years of age; average age, 4 years) with CD
responded to DQ2.5-glia-a1a/a2 epitopes regarded as
immunodominant in adults with CD. However, in the same
study only 2 of 4 TCL isolated from adults with CD
responded to these a-gliadin epitopes, contrasting with
17 of 17 (100%) TCLs isolated from adult NorwegianCD donors,9 suggesting that methodological differences
could contribute to these differences. Artifacts can re-
sult from prolonged in vitro culture and the use of mito-
gens, which may expand naïve T cells and affect the
composition and function of the T-cell population of inter-
est.23 Although epitope spreading was postulated to account
for the heterogeneous gluten peptide responses they
observed in children,15 our ﬁndings suggest the repertoire
of gluten-speciﬁc T cells is well established by the time CD
is diagnosed. As epitope spreading typically occurs within
weeks, not years, of an initial immune response, it is
possible that the gluten-speciﬁc immune response at the
earliest phase of CD development is different from the stable
Figure 6. Similar TCR bias occurred in gluten-speciﬁc T cells from children and adults with CD. (A) Single IFN-g–producing
DQ2.5-glia-a1a/a2-speciﬁc CD4þ T cells were isolated by ﬂuorescence-activated cell sorting for multiplex PCR. Sequencing
analysis of the TCR Va (TRAV) and Vb chains (TRBV) expressed by this population was performed in 3 wheat-challenged
volunteers with CD (subjects C14, C27, and A1). The compositions of the TRAV and TRBV usage are shown in separate
pie charts, with individual chains represented by different colors. The most commonly used chains are listed within the pie
charts. (B) Simpson’s diversity index for Va and Vb CDR3 sequences were calculated for the same individuals as in A.
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who have CD prior to clinically recognizable disease is
difﬁcult, and we have shown previously that the successful
induction of an in vivo recall response requires participants
to be following a gluten free diet for at least several weeks
prior to an oral wheat challenge.12 This means, in practice,
only the stable memory T-cell response can be interrogated.
Nevertheless, native peptides may still be important for
disease development. In a humanized HLA-DQ8 transgenic
mouse model,28 immunization with a native gluten peptide
comprising the DQ8-glia-a1 epitope (QGSFQPSQQ) can re-
cruit a T-cell population that is cross-reactive and substan-
tially more reactive against the corresponding deamidated
peptides. It is possible in early disease T cells are recruited
by native peptide, triggering inﬂammation and tTG release,
and then continue to be activated by more immunogenic
deamidated peptides.
In Italian children with CD peptides containing DQ2.5-
glia-a1/2, DQ2.5-glia-u1/2 or homologs commonly eliciteda signiﬁcant IFN-g response after wheat challenge. Although
bioactivity was enhanced by deamidation and peptides were
typically more immunogenic than whole protein, in contrast
to the Australian cohort, W02 and W03 (containing DQ2.5-
glia-a1/2 and DQ2.5-glia-u1/2) did not induce >70% of
the maximal peptide response in the majority of children
tested. Possible explanations include the smaller sample
size, higher background responses (generally >10 spot
forming units/well) that elevated the cutoff level required
to establish a positive response, and potential differences in
the amount and composition of the bread ﬂour used for the
wheat gluten challenge. Collectively, the data supports the
importance of a focused immune response after wheat
ingestion to dominant a- and u-gliadins, and the importance
of deamidation for gluten peptide bioactivity in children
with CD.
It has been reported that the HLA-DQ2.5 gene dose
has a strong quantitative effect on the magnitude of
gluten-speciﬁc T-cell responses.29 Although the overall
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higher in HLA-DQ2.5 homozygotes the EC50s were not
signiﬁcantly lower. Responses to subdominant peptides in
gliadin, hordein, and secalin appeared broader in homo-
zygotes, possibly due to more efﬁcient presentation of
these peptides on the surface of antigen presenting cells,
or to more efﬁcient priming/expansion of cognate T cells
in HLA-DQ2.5 homozygous CD. In some reports, HLA-
DQ2.5 homozygosity is associated with a younger age
and more severe phenotype at diagnosis.30 We did not ﬁnd
an association between homozygosity and earlier disease
onset or more severe histology at diagnosis, although the
sample of HLA-DQ2.5 homozygous volunteers was rela-
tively small.
High redundancy of gluten peptide recognition by T cells
speciﬁc for a small selection of dominant peptides un-
derpins the feasibility of peptide-based applications in CD.13
In adults with CD, we have shown the polyclonal T-cell
response induced after gluten challenge speciﬁc for W02,
W03, and B08 (from barley; EPEQPIPEQPQPYPQQ) were
equivalent to as much as 90% of that elicited by optimal
concentrations of deamidated wheat gliadin, barley hordein,
or the most immunogenic rye secalin fraction (u-secalin).
Moreover, TCCs isolated from adults with CD speciﬁc for
DQ2.5-glia-a1a/a2, DQ2.5-glia-u1/ u2, DQ2.5-hor-3, and a
rye epitope (DQ2.5-sec-1) recognize almost 90% of the T-
cell stimulatory gluten peptides from all of the toxic cereals
in CD. Here we showed that TCC speciﬁc for the immuno-
dominant wheat T-cell epitopes in CD children share the
same degree of cross-reactivity as TCC isolated from CD
adults. The ﬁndings suggest a discrete number of dominant
peptides can replicate the whole gluten response in children
with CD as they can in adults.
Biased TCR gene usage has previously been observed
in DQ2.5-glia-a2-speciﬁc T cells,2 with overusage of the
TRAV26-1 and TRBV7-2 gene segments and conservation of
a non-germline-encoded Arg residue in the CDR3b loop,
suggesting structural constraints are involved during
in vivo TCR selection.21,31,32 However, it is unclear
whether selective outgrowth as a consequence of exten-
sive antigen exposure prior to diagnosis of CD aids in the
selection of cells expressing an optimal TCR. We detected
identical CDR3b sequences within the DQ2.5-glia-a1a/a2-
speciﬁc T-cell populations in pediatric and adult CD vol-
unteers. Sequences were also shared with those previously
described in a tetramer-selected T-cell population isolated
from adults with CD.21 Sorting by IFN-g secretion enables
selection of functional gluten-speciﬁc T cells that is not
possible in tetramer-based assays.33 Although we selected
high-gluten–responding donors that could potentially bias
TCR selection, the public sequences obtained suggest this
was not the case. Diversity scores were similar between
the pediatric and adult CD donors, suggesting that the
level of TCR diversity had reached similar levels and that
disease had progressed to a similar level in each individ-
ual. Importantly, there seemed to be no continued reper-
toire narrowing or afﬁnity maturation in adults that had
not yet occurred in children, despite additional chances of
repeated exposure to antigen. Collectively, these datafurther validated the public usage of these CDR3 se-
quences in the DQ2.5-a2-speciﬁc T-cell response in CD
donors, conﬁrmed the importance of immunodominant
epitopes shaping the selection of TCRs, and supported
consistency of T-cell responses to dominant wheat gluten
peptides across all ages.
Future studies are required to assess the consistency of
immune responses to immunodominant rye secalin and
barley hordein T-cell epitopes, previously identiﬁed in
adults,13 after consumption of these grains in children with
CD. Furthermore, this study conﬁrms previous observations
that the presence and severity of symptoms after gluten
challenge correlates poorly with the T-cell response and
greater insight into the mechanisms responsible for gluten-
induced symptoms in CD are necessary.
We show the speciﬁcity of the gluten-speciﬁc T-cell
response reactivated by oral wheat challenge in children
with CD does not differ from adults. Stability of epitopes
recognized by gluten-reactive CD4þ T cells after diagnosis of
CD whether in childhood or adult life indicates clinical ap-
plications of gluten-derived T-cell epitopes should be rele-
vant to CD patients of all ages.
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Supplementary Material and Methods
Pediatric Wheat Challenge and Blood Collection
The amount of bread consumed daily was modiﬁed for
younger ages: 3–5 years, 1 slice of bread (w3 g of gluten/
day); 6–10 years, 2 slices (w 6 g of gluten/day); and 11–18
years, 3 slices (w 9 g of gluten/day). This corresponded to a
similar amount of daily gluten intake across all age groups
(w 0.2 g/kg gluten based on median weight using a weight-
for-age percentile chart). Six- to 10-year-old Italian children
ate 3 slices of bread (w9 g of gluten/day), and 11- to
18-year-olds ate 4 slices of bread (w12 g of gluten/day).
Blood for T-cell studies was collected in lithium heparin
Vacutainers (Becton-Dickinson, Hunt Valley, MD) before
(Day 0 [D0]) and 6 days after (D6) commencing the oral
challenge, and volume was determined by weight based on
World Health Organization guideline.S1 Volunteers
completed symptom diaries, recording symptom type and
severity (mild, moderate, or severe) daily until D6.
Antigens
The screening library was custom synthesized, and the
identity of each peptide was conﬁrmed by liquid
chromatography-mass spectrometry (GL Biochem, Minhang,
China). Additional high-quality (>80%) peptides were syn-
thesised by Pepscan (Lelystad, the Netherlands) or GL Bio-
chem. Comprehensive gliadin (n¼ 1535), hordein (n¼ 1444),
and secalin (n¼ 350) peptide libraries consisting of wild-type
and in silico-deamidated sequences13 were used to screen
T-cell clones (TCC). Whole gluten (a generous gift from A.
Tatham) was assessed in addition to gliadin (catalog 101778;
ICN Biomedicals, Aurora, OH) to determine whether untested
glutenin peptides contributed to the whole gluten response.
Gluten and gliadin were digested with chymotrypsin and
deamidated with tTG as previously described.10,12
IFN-g ELISpot Assay
Peripheral bloodmononuclear cells (PBMC)were isolated
from whole blood by using Ficoll-Paque Plus density-
gradient centrifugation (GE Healthcare, Buckinghamshire,
UK). IFN-g ELISpot (Mabtech, Cincinnati, OH) assays were
performed and analyzed as previously described.13 Brieﬂy,
PBMC were incubated overnight with or without individual
peptides (50 mg/mL), and with positive controls Tetanus
toxoid (CSL, Behring, Australia) and phytohemagglutinin-L
(PHA-L; Sigma-Aldrich, St. Louis, MO). Spot-forming units
(SFU) in individual wells were counted using an automated
ELISPOT reader (AID ELISpot reader system; Autoimmun
Diagnostika GmbH, Strassberg, Germany; or in Italy, using an
Aelvis ELISpot reader, Hannover, Germany). Wells showing
more than 10 SFU and >3 the SFU counted in wells con-
taining PBMC incubated with medium alone were regarded
as positive. Dominance scores for each peptide were deﬁned
using the IFN-g response elicited as a proportion of the most
active peptide screened and then averaged across each
volunteer group. SFUwere adjusted to 1million PBMC plated
to enable comparisons. Median effective concentration
(EC50) values, representing the half maximal peptide con-
centration, were calculated using Prism version 6.0 software
(GraphPad, LaJolla, CA) on a dose curve containing 8 peptide
concentrations ranging from 0.1 to 50 mg/mL.
T-Cell Cloning
TCC were generated as previously described.13 Brieﬂy,
carboxyﬂuorescein succinimidyl ester (CFSE)-labeled PBMC
were incubated with antigen for 7 days, after which
proliferating single cells were incubated in the presence of
IL-2, IL-4, anti-CD3 monoclonal antibody, irradiated allo-
geneic PBMC, and JY-EBV (an Epstein-Barr virus-immor-
talized B cell line), followed by expansion. TCC were tested
by ELISpot for speciﬁcity and to determine HLA-DQ2.5
restriction. TCC also were tested in the presence of anti-
human HLA-DQ or HLA-DR blocking antibodies. TCC clon-
ality and TCR Vbeta usage was tested by PCR or IOTest Beta
Mark TCR V kit (Beckman Coulter, Sykesville, MD), and
minimal epitopes were deﬁned with lysine scans.S2
IFN-g Secretion Assay
Either fresh or cryopreserved PBMC from known T-cell
responders were rested overnight, and CD4þ T cells were
enriched using an EasySep negative selection human CD4þ
T-cell enrichment kit (Stem Cell Technologies, Vancouver,
BC, Canada), following manufacturer’s recommendations.
CD4þ T cells were stimulated or not with 50 mg/mL peptide,
in addition to 10 mg/mL puriﬁed anti-CD28 antibody and
1.25 mg/mL anti-CD49d antibody (both from Biolegend, San
Digo, CA), and autologous PBMC at a 1:1 ratio, in 96-well
round-bottom plates in replicate wells containing a ﬁnal
volume of 150 mL of media containing 20 mg/mL DNase I
(Roche, Basel, Switzerland) for 4 hours. The MACS IFN-g
secretion assay detection kit (ﬂuorescein isothiocyanate)
human (Miltenyi Biotec, Bergisch Gladbach, Germany) was
used to enable cell sorting of IFN-g secreting,
gluten-speciﬁc CD4þ T cells, following manufacturer’s rec-
ommendations. Cells were stained with IFN-g-FITC (in kit),
CD4-APC and CD14-PerCP (BD Biosciences), CD69-PECy7
(Biolegend), and propidium iodide (Sigma). Gluten-speciﬁc
(IFN-gþCD69þCD4þ) cells were single-cell sorted into
96-well PCR (Eppendorf) plates up to 80 wells and 1 col-
umn left empty as nontemplate controls, on a FACS Aria
(Becton-Dickinson) machine. Wells were capped with strip
lids and stored frozen for later processing.
TCR sequencing
cDNA sequences encoding the alpha and beta chains of
the TCR on sorted single cells were determined using a
nested multiplex PCR as previously described.S3 Simpson’s
diversity index (SDI) is calculated as D ¼ Si [(ni {ni  1})/
(N {N  1})] where ni is the number of sequences in the ith
clonotype, and N is the total number of sequences in the
whole population.S4 This is a measure of diversity, which is
deﬁned as a combination of richness (the number of
different clonotypes within a population) and evenness (the
distribution of the clonotypes) and is expressed as 1-D so
that a higher number corresponds to greater diversity.
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Supplementary Figure 1. Poor response to tetanus toxoid
predicts lack of response to gluten peptides. Volunteers were
separated into responders (n ¼ 31) or non-responders (n ¼ 9)
based on the IFN-g ELISpot response to gluten after oral
wheat challenge. Responses to the positive control antigen
tetanus toxoid were compared on D6 following wheat chal-
lenge. Line depicts response cut-off. Median response with
interquartile range is shown.
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